Aziz Pirani, MD
Family Medicine · Lilburn, GANPI 1760622096
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,527 of the $8,625 with a category attached, or 75.7%. It is spread thinly across 32 manufacturers, the largest accounting for just 21.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $2,865 and has fallen 56.6% since, to $1,243 in 2025. Among family medicine clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 416 payments — averaging $20.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Modernatx, Inc.$2K
- AstraZeneca$1K
- Amgen$640
- Novo Nordisk$588
- Boehringer Ingelheim$548
- Lilly USA, LLC$543
- plus $3K from 26 others
Across 265 payments — averaging $7871.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Seqirus USA Inc$782K
- Modernatx, Inc.$643K
- Bavarian Nordic A/s$507K
- Genentech, Inc.$84K
- AstraZeneca$70K
What the payments were for
- Travel & lodging$2,00823%
- Food & beverage$6,52776%
- Education$911%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Modernatx, Inc. | 5 | $1,877 |
| AstraZeneca | 60 | $1,380 |
| Amgen(2 entities) | 46 | $640 |
| Novo Nordisk | 65 | $588 |
| Boehringer Ingelheim | 31 | $548 |
| Lilly USA, LLC | 34 | $543 |
| Merck | 32 | $504 |
| GSK | 23 | $400 |
| Pfizer | 21 | $398 |
| Johnson & Johnson | 20 | $344 |
| Sanofi-aventis U.S. LLC | 13 | $227 |
| Amarin Pharma, Inc. | 12 | $194 |
| Abbott | 6 | $121 |
| Xeris Pharmaceuticals, Inc. | 6 | $116 |
| Astellas Pharma US Inc | 4 | $97 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $90 |
| Shield Therapeutics Inc | 4 | $73 |
| Arbor Pharmaceuticals, Inc. | 5 | $72 |
| Idorsia Pharmaceuticals US Inc | 3 | $70 |
| Exact Sciences | 3 | $61 |
| Novartis | 3 | $47 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $42 |
| Phadia US Inc. | 2 | $35 |
| Dexcom, Inc. | 2 | $33 |
| Sanofi Pasteur Inc. | 1 | $28 |
| Corcept Therapeutics | 1 | $20 |
| Genentech USA, Inc. | 1 | $18 |
| Azurity Pharmaceuticals, Inc. | 1 | $16 |
| Linus Health, Inc. | 1 | $16 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Sumitomo Pharma America, Inc. | 1 | $1 |
How this compares
$8,625 in reported general payments places this provider in the 90th percentile of 3,111 family medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 160 | $233,799 |
| JardianceEmpagliflozin | 134 | $203,067 |
| JanuviaSitagliptin Phosphate | 108 | $162,524 |
| OzempicSemaglutide | 71 | $107,876 |
| TrulicityDulaglutide | 30 | $52,999 |
| MyrbetriqMirabegron | 55 | $51,397 |
| EliquisApixaban | 35 | $48,551 |
| RybelsusSemaglutide | 20 | $45,810 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 56 | $43,515 |
| LinzessLinaclotide | 29 | $37,509 |
| ProliaDenosumab | 22 | $37,351 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 117 | $36,512 |
| MounjaroTirzepatide | 18 | $34,957 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 121 | $27,262 |
| BelsomraSuvorexant | 43 | $25,764 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Symbicort | $1,380 | $239,633179 claims |
| Boehringer IngelheimJardiance, Tradjenta | $548 | $220,415149 claims |
| MerckJanuvia, Belsomra | $504 | $188,289151 claims |
| Novo NordiskOzempic, Rybelsus | $588 | $153,68591 claims |
| GSKTrelegy Ellipta, Arexvy, Shingrix, Breo Ellipta | $400 | $116,628313 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $543 | $87,95648 claims |
| Astellas Pharma US IncMyrbetriq | $97 | $51,39755 claims |
| PfizerEliquis | $398 | $48,55135 claims |
| AmgenProlia | $640 | $37,35122 claims |
| Johnson & JohnsonXarelto | $344 | $25,01320 claims |
| NovartisEntresto | $47 | $20,68813 claims |
| Sanofi-aventis U.S. LLCLantus | $227 | $3,45918 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,111 family medicine providers in Georgia.
Other family medicine in Lilburn
- Jeffrey KingsleyColumbus$404K
- Debbie HaginsSavannah$279K
- Yolanda WadeTyrone$233K
- Julian HutchinsWarrenton$222K
- Nadine Halliburton-FosterCumming$219K
- Contessa MetcalfeAtlanta$157K
- Elmore AlexanderStone Mountain$155K
- Bantwal BaligaColumbus$115K
- Avril CampbellFort Benning$108K
- Mitzi RubinMarietta$103K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.